查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球磁共振成像造影剂市场 - 2023-2030 年
市场调查报告书
商品编码
1316235

全球磁共振成像造影剂市场 - 2023-2030 年

Global MRI Contrast Media Agents Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概述

2022 年，全球核磁共振成像造影剂市场规模达到 21 亿美元，预计到 2030 年将实现利润丰厚的增长，达到 35 亿美元。在预测期内（2023-2030 年），全球核磁共振成像造影剂市场预计将呈现 6.9% 的复合年增长率。

由于核磁共振成像技术的改进，包括高场强核磁共振成像系统、多参数成像和功能性核磁共振成像，核磁共振成像的临床应用日益增多。由于这些发展，人们现在需要更强效、更专业的造影剂，以提供更好的图像质量和诊断精度。

市场动态

核磁共振成像造影剂的 FSA 批准推动了预测期内全球核磁共振成像造影剂市场的增长

例如，2023 年 2 月，Bracco 公司和加柏公司几乎同时推出了名为钆喷酸醇的全新 MRI 造影剂。这两种造影剂基于相同的分子结构，只需钆的一半剂量就能进行造影剂增强型核磁共振成像扫描，尽管两家公司都以各自的品牌销售钆喷酸酯。

美国食品和药物管理局（FDA）已经批准了一种新型磁共振成像（MRI）造影剂 - 钆喷酸诺，它具有良好的弛豫性和较低的钆剂量。

活跃的主要企业为全球磁共振成像造影剂提供了市场增长机会

例如，2023 年 4 月，GE HealthCare 宣布推出 Pixxoscan（钆布醇），这是一种用于磁共振成像（MRI）的大环、非离子型钆基造影剂（GBCA）。Pixxoscan 已在奥地利获得销售许可，正在等待批准，目前已通过监管分散程序 (DCP) 评估，将于 2023 年在其他欧洲国家上市。

根据审查结果，Pixxoscan 在质量和数量上与 Gadovist 参考产品具有相同的活性成分和辅料成分，以及相同的药物形式。

COVID-19 影响分析

COVID-19 大流行对核磁共振成像造影剂市场产生了重大影响。疫情改变了资源分配和医疗保健的优先次序。为了支持与 COVID-19 相关的病人护理和分流，核磁共振成像扫描仪和造影剂等成像资源被重新分配。用于非 COVID-19 的核磁共振成像造影剂的供应和应用可能会受到资源重新分配的影响。

俄乌冲突分析

俄乌战争对核磁共振成像造影剂市场的影响是复杂和多方面的。冲突环境可能会阻碍人们使用核磁共振成像扫描仪等尖端医疗设备。如果医疗设施或医疗基础设施遭到破坏或无法进入，冲突会限制受影响地区使用核磁共振成像造影剂。

目 录

第 1 章：研究方法与范围

  • 研究方法
  • 报告的研究目标和范围

第2章：定义和概述

第3章：执行摘要

  • 按产品分類的片段
  • 按类型划分
  • 按适应症划分
  • 按最终用户分类
  • 按地区划分

第四章：动态

  • 影响因素
    • 驱动因素
      • 慢性疾病增加
    • 制约因素
      • 磁共振成像造影剂的不良反应
    • 机会
      • 技术进步
    • 影响分析

第 5 章：行业分析

  • 波特五力分析法
  • 供应链分析
  • 未满足的需求
  • 监管分析

第 6 章：COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • COVID-19 期间的情景
    • COVID-19 后的情况
  • COVID-19 期间的定价动态
  • 供求关系
  • 大流行期间与市场相关的政府倡议
  • 制造商的战略倡议
  • 结论

第 7 章 ：俄乌战争分析

第8章：人工智能分析

第9章：按产品分类

  • 顺磁剂
  • 超顺磁性制剂

第十章：按适应症分类

  • 临床
  • 临床前

第 11 章：按适应症分类

  • 癌症
  • 胃肠道
  • 肝胆
  • 神经系统成像
  • 其他

第 12 章：按最终用户分类

  • 医院
  • 成像中心
  • 其他

第 13 章 ：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第 14 章：竞争格局

  • 竞争格局
  • 产品基准
  • 公司份额分析
  • 主要发展和战略

第 15 章 ：公司简介

  • GE Healthcare
    • 公司概况
    • 产品组合和说明
    • 财务概况
    • 主要发展
  • Bracco Imaging SPA
  • Bayer AG
  • Guerbet
  • Lantheus Medical Imaging
  • Unijules Life Sciences
  • B. Chemicals and Pharmaceuticals Ltd.
  • SANOCHEMIA Pharmazeutika GmbH
  • Taejoon Pharm
  • Jodas Expoim

第 16 章 ：附录

简介目录
Product Code: MI6532

Market Overview

The global MRI contrast media agents market reached US$ 2.1 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 3.5 billion by 2030. The global MRI contrast media agents market is expected to exhibit a CAGR of 6.9% during the forecast period (2023-2030).

The clinical uses of MRI have increased as a result of improvements in MRI technology, including high-field MRI systems, multi-parametric imaging, and functional MRI. Because of these developments, there is now a desire for more potent and specialized contrast media agents that can deliver better image quality and diagnostic precision.

Market Dynamics

FSA Approval For MRI Contrast Media Agents is Boosting the Global MRI Contrast Media Agents Market Growth During the Forecast Period

For instance, in February 2023, the unveiling of a brand-new MRI contrast agent called gadopiclenol that Bracco and Guerbet jointly created took place almost simultaneously. The agents are based on the same molecular structure and offer the possibility of contrast-enhanced MRI scans at half the dose of gadolinium, despite the fact that each business is marketing gadopiclenol under its respective brand names.

The Food and Drug Administration (FDA) has approved gadopiclenol, a novel magnetic resonance imaging (MRI) contrast agent that delivers good relaxivity and a lower gadolinium dose.

Active Key Players Provide Global MRI Contrast Media Agents with Market Growth Opportunities

For instance, in April 2023, GE HealthCare announced the availability of Pixxoscan (gadobutrol), a macrocyclic, non-ionic gadolinium-based contrast agent (GBCA) for magnetic resonance imaging (MRI). With a marketing license in place in Austria and pending approval, Pixxoscan has undergone regulatory decentralized procedure (DCP) evaluation and will be available in other European nations in 2023.

According to a review, it has the same active ingredient and excipient composition in terms of both quality and quantity, as well as the same pharmaceutical form, as the Gadovist reference product.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the MRI contrast media agents market. The epidemic has caused a change in the allocation of resources and healthcare priorities. In order to support patient care and triage linked to COVID-19, imaging resources such as MRI scanners and contrast media agents were reallocated. The availability and application of MRI contrast media agents for non-COVID-19 use may be impacted by this resource reallocation.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the MRI contrast media agents market is complex and multifaceted. Conflict circumstances may prevent people from using cutting-edge medical equipment, such as MRI scanners. Conflict can restrict the use of MRI contrast media agents in impacted areas if medical facilities or healthcare infrastructure are destroyed or inaccessible.

Segment Analysis

The global MRI contrast media agents market is segmented based on type, product, indication, end-user, and region.

The Superparamagnetic Agent Segment is Holding 42.7% market share in the Market in 2022

The superparamagnetic agents segment accounted for approximately 42.7% of the MRI contrast media agents market share in 2022. When exposed to an external magnetic field, superparamagnetic substances can align with it and quickly demagnetize when the field is withdrawn. Superparamagnetic agents do not show any residual magnetization, in contrast to ferromagnetic materials, which do so even in the absence of an external field. The main purpose of superparamagnetic substances is to improve contrast in MRI scans.

These substances aggregate in certain organs or blood vessels of interest when given intravenously, including the liver, spleen, lymph nodes, and blood arteries. They produce a local magnetic field distortion because of their magnetic characteristics, which changes the relaxation durations of adjacent water protons. The structures or regions holding the contrast agent are now easier to discern in the subsequent MRI images as a result of this modification, which results in a change in signal intensity.

Geographical Analysis

Advancements in MRI Contrast Media Agents Dominate the North American Region

North America is expected to dominate the MRI contrast media agents market, accounting for around 39.4% of this market. Modern medical imaging methods, such as MRI, are widely used throughout North America. In several therapeutic specialties, including neurology, cardiology, cancer, and musculoskeletal imaging, MRI scans are frequently employed. The market for MRI contrast media agents is driven by the rising use of MRI scans in North America. The development of medical imaging technology is leading the way in the region.

The region's research and development efforts are concentrated on creating novel contrast media agents with enhanced imaging characteristics, safety profiles, and targeted targeting abilities. The development of MRI contrast media agents is aided by the presence of top pharmaceutical and medical device businesses in the region.

Competitive Landscape

The major global players in the market include: GE Healthcare, Bracco Imaging SPA, Bayer AG, Guerbet, Lantheus Medical Imaging, Unijules Life Sciences, B. Chemicals and Pharmaceuticals Ltd., Sanochemia Pharmazeutika GmbH, Taejoon Pharm, and Jodas Expoim among others.

Why Purchase the Report?

  • To visualize the global MRI contrast media agent's market segmentation based on the product, type, indication, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of MRI contrast media agents market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global MRI contrast media agents market report would provide approximately 69 tables, 66 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Type
  • 3.3. Snippet by Indication
  • 3.4. Snippet by End-user
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing chronic diseases
    • 4.1.2. Restraints
      • 4.1.2.1. Adverse reactions to MRI contrast media agents
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Product

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 9.1.2. Market Attractiveness Index, By Product
  • 9.2. Paramagnetic Agents*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Superparamagnetic Agents

10. By Indication

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.1.2. Market Attractiveness Index, By Indication
  • 10.2. Clinical*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Preclinical

11. By Indication

    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.1.2. Market Attractiveness Index, By Indication
  • 11.2. Cancer*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Gastrointestinal
  • 11.4. Hepatobiliary
  • 11.5. Neurological Imaging
  • 11.6. Others

12. By End-user

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 12.1.2. Market Attractiveness Index, By End-user
  • 12.2. Hospitals*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Imaging Centers
  • 12.4. Other

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.7.1. U.S.
      • 13.2.7.2. Canada
      • 13.2.7.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.7.1. Germany
      • 13.3.7.2. U.K.
      • 13.3.7.3. France
      • 13.3.7.4. Italy
      • 13.3.7.5. Spain
      • 13.3.7.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.7.1. Brazil
      • 13.4.7.2. Argentina
      • 13.4.7.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.7.1. China
      • 13.5.7.2. India
      • 13.5.7.3. Japan
      • 13.5.7.4. Australia
      • 13.5.7.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Product Benchmarking
  • 14.3. Company Share Analysis
  • 14.4. Key Developments and Strategies

15. Company Profiles

  • 15.1. GE Healthcare*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Bracco Imaging SPA
  • 15.3. Bayer AG
  • 15.4. Guerbet
  • 15.5. Lantheus Medical Imaging
  • 15.6. Unijules Life Sciences
  • 15.7. B. Chemicals and Pharmaceuticals Ltd.
  • 15.8. SANOCHEMIA Pharmazeutika GmbH
  • 15.9. Taejoon Pharm
  • 15.10. Jodas Expoim

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us